A D.C. federal judge on Thursday appeared skeptical about Vanda Pharmaceuticals’ assertions that the company’s future is at risk if it must wait for the U.S. Food and Drug Administration (FDA) to review its challenge. The dispute concerns the FDA’s approval of a generic version of Vanda’s sleep medication, a decision Vanda claims could seriously jeopardize its market standing and financial health.
For further details on the judicial proceedings and implications for Vanda Pharmaceuticals, you can read the original article.